Covidien's Two Neurovascular Trial Enrolments on Track - Analyst Blog

A generic image of a stock chart
Credit: Shutterstock photo

Covidien plc ( COV ) has started enrolling patients for two clinical trials designed to highlight the safety and effectiveness of its advanced neurovascular solutions. The PREMIER Prospective study is designed to evaluate Covidien's Pipeline embolization device while the STRATIS Registry for Endovascular Stroke Devices will evaluate all its market-released stroke devices.

The PREMIER Prospective Study

The PREMIER study is an international Investigational Device Exemption clinical study which will assess the safety and efficacy of Covidien's Pipeline device in the treatment of unruptured, small and medium wide-necked intracranial aneurysms.

The first patient enrolled in the PREMIER study was treated at Baptist Medical Center in Jacksonville, FL. The study will eventually register up to 141 patients at 20 global sites in an effort to provide valuable clinical evidence in a new population of aneurysms.

The STRATIS Registry

The STRATIS Registry is a prospective, multi-center, non-randomized, observational registry intended to evaluate the use of Covidien endovascular stroke devices in patients diagnosed with acute ischemic stroke. Notably, Covidien's current endovascular stroke device in the U.S. is the Solitaire 2 revascularization device.

Baptist Health Lexington in Kentucky enrolled the first patient in the STRATIS Registry. Going forward, as many as 60 U.S. sites are expected to participate in the STRATIS Registry, which will enroll up to 1,000 patients to collect clinical outcomes for interventional stroke patients in a real world setting.

Going Forward

Covidien continues to design outcome-based clinical studies to confirm the real world safety and efficiency of its highly-developed neurovascular technologies. It intends to explore new applications for unmet medical needs.

Currently, Covidien carries a Zacks Rank #3 (Hold). Better-ranked stocks in the medical products industry include ICU Medical ( ICUI ), Abaxis, Inc. ( ABAX ) and Eagle Pharmaceuticals ( EGRX ). ICU Medical sports a Zacks Rank #1 (Strong Buy), while both Abaxis and Eagle Pharmaceuticals carry a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

COVIDIEN PLC (COV): Free Stock Analysis Report

ABAXIS INC (ABAX): Free Stock Analysis Report

ICU MEDICAL INC (ICUI): Free Stock Analysis Report

EAGLE PHARMACT (EGRX): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

Learn More